Administration of dendritic cells in cancer nodules in hepatocellular carcinoma
/in Hepatocellular Carcinoma, International Publications[In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine]
/in Dendritic Cells, International Publications, Multiple MyelomaGenetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma
/in International Publications, Malignant LymphomaDendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses
/in Hepatocellular Carcinoma, International PublicationsVaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
/in Dendritic Cells, International Publications, Malignant MelanomaB cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells
/in International Publications, Malignant Lymphoma[Current status of hyperthermia for therapy of brain tumor]
/in Glioblastoma, International PublicationsImmune-related effects of local hyperthermia in patients with primary liver cancer
/in Hepatocellular Carcinoma, International PublicationsImmune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
/in International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer